【摘要】 目的比较米氮平与帕罗西汀治疗抑郁症的临床疗效和安全性。方法将86例抑郁症患者随机分为米氮平组与帕罗西汀组,每组各43例,疗程8周,以汉密尔顿抑郁量表(HAMD)和不良反应量表(TESS)评定在治疗前和治疗后1周、2周、4周及8周末的疗效与不良反应。结果经过8周治疗,显效率和治愈率米氮平组分别为82.2%和65.8%,帕罗西汀组分别为79.1%和63.3%,差异无统计学意义(P>0.05);治疗后两组HAMD评分均显著低于治疗前,差异有统计学意义(P<0.01);治疗后1周末米氮平组HAMD评分显著低于帕罗西汀组(P<0.05);而治疗2周后两组间HAMD评分差异无统计学意义(P>0.05)。两组不良反应无统计学意义(P>0.05)。结论米氮平治疗抑郁症安全有效,且起效快,不良反应轻,值得应用。更多还原

【Abstract】 Objective To compare clinical efficacy and safety of mirtazapine and paroxetine in the treatment of depression. Methods 86 patients with depression were randomly treated with mirtazapine or paroxetine(each group 43 patients).The course of treatment was 8 weeks. Hamilton depression rating scale(HAND) and side effects scale(TESS) were used to assess the efficacy and side effects respectively before treatment and after treatment 1, 2, 4, 8 weekends. Results The significant efficiency and cure rate of mirtazapine and paroxetine were 82.2%, 65.8% and 79.1%, 63.3% respectively at 8 weekend after treatment(P >0.05),The scores of HAMD for both groups were obviously decreased after treatment(P <0.01). HAMD in mirtazapine group were statistically lower than those in paroxetine group at the firsth weekend(P<0.05).The differences became insignificant after 2 weeks(P>0.05). There was no significant difference in adverse reactions between both groups(P>0.05). Conclusion Mirtazapine is safe and effective in the treatment of depression,with less adverse reactions,is worthy of application.更多还原